Literature DB >> 6097857

Contrast medium causes the apparent increase in beta-endorphin levels in human cerebrospinal fluid following brain stimulation.

Raymond A Dionne1, Gregory P Mueller, Ronald F Young, Richard P Greenberg, Kenneth M Hargreaves, Richard Gracely, Ronald Dubner.   

Abstract

Levels of beta-endorphin immunoreactivity in cerebrospinal fluid were measured in 12 chronic pain patients undergoing the surgical implantation of an electrode into the periventricular gray matter. Cerebrospinal fluid fractions were collected following placement of a cannula into the third ventricle, following injection of metrizamide contrast medium into the ventricles, following implantation of the electrode, and following electrical stimulation. A second set of samples was collected on a non-surgical day before and after stimulation. Levels of beta-endorphin immunoreactivity increased significantly from baseline levels to post-electrode implantation in one group of patients, but no significant change was seen following the onset of stimulation. Immunoreactivity increased significantly following metrizamide injection in a second group and was still elevated, in comparison to baseline, following electrode placement, but no increase was seen following the onset of stimulation. Levels of immunoreactive beta-endorphin did not increase in either group after stimulation on a post-surgical day, despite consistent reports of pain relief. Addition of metrizamide or a related contrast medium, iothalamate meglumine (Conray) to the beta-endorphin radioimmunoassay revealed that both compounds interfered with antigen-antibody binding and also quenched the gamma radiation emitted by iodinated peptide ligands. Due to these combined effects, the contrast media alone produced results similar to those of the beta-endorphin standard. Moreover, similar observations were made when contrast media were incorporated into radioimmunoassays for met-enkephalin, dynorphin and cholecystokinin octapeptide. These findings indicate that increased levels of beta-endorphin in cerebrospinal fluid are not directly associated with patient report of pain relief following periventricular gray stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097857     DOI: 10.1016/0304-3959(84)90109-X

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  6 in total

Review 1.  Invasive brain stimulation for the treatment of neuropathic pain.

Authors:  Jean-Paul Nguyen; Julien Nizard; Yves Keravel; Jean-Pascal Lefaucheur
Journal:  Nat Rev Neurol       Date:  2011-09-20       Impact factor: 42.937

Review 2.  Neuropathic pain and deep brain stimulation.

Authors:  Erlick A C Pereira; Tipu Z Aziz
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

Review 3.  Motor cortex and deep brain stimulation for the treatment of intractable neuropathic face pain.

Authors:  Laneshia Thomas; Jonathan M Bledsoe; Matt Stead; Paola Sandroni; Deborah Gorman; Kendall H Lee
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

Review 4.  Deep brain stimulation for chronic pain: intracranial targets, clinical outcomes, and trial design considerations.

Authors:  Orion Paul Keifer; Jonathan P Riley; Nicholas M Boulis
Journal:  Neurosurg Clin N Am       Date:  2014-10       Impact factor: 2.509

5.  Brain Stimulation Therapy for Central Post-Stroke Pain from a Perspective of Interhemispheric Neural Network Remodeling.

Authors:  Takashi Morishita; Tooru Inoue
Journal:  Front Hum Neurosci       Date:  2016-04-21       Impact factor: 3.169

Review 6.  Role of Neuromodulation and Optogenetic Manipulation in Pain Treatment.

Authors:  Sufang Liu; Changsheng Li; Ying Xing; Yanqing Wang; Feng Tao
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.